8 active not recruiting, 2 recruiting, 1 unknown, 1 withdrawn. 12 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Active not recruiting 8, Recruiting 2, Unknown 1, Withdrawn 1 |
| Phase 1 | 2 | Active not recruiting 2 |
Follow selpercatinib: new trials by email Literature Review of selpercatinib trials Research Report on selpercatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC Selpercatinib, Sodium Iodine I-131, rhTSH - Thyroid Cancer, Thyroid Carcinoma | Phase 2 | Recruiting | Massachusetts General Hospital | 30 | 2023-03-01 | 2024-12-12 |
| Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer Carboplatin, Pemetrexed, Selpercatinib - Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 2 | Withdrawn | SWOG Cancer Research Network | 2022-07-25 | 2024-07-09 | |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-10-09 |
| Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer Quality-of-Life Assessment, Questionnaire Administration, Selpercatinib - Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2021-02-26 | 2026-05-20 |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy Erlotinib, Trastuzumab, Trastuzumab emtansine - Breast Cancer, Gastrointestinal Cancer | Phase 2 | Unknown | Fondazione per la Medicina Personalizzata | 400 | 2020-10-07 | 2023-10-03 |
| Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) Selpercatinib - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Active not recruiting | SWOG Cancer Research Network | 124 | 2020-04-08 | 2026-03-23 |
| A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation Selpercatinib - Solid Tumor, Medullary Thyroid Cancer | Phase 2 | Active not recruiting | Eli Lilly and Company | 77 | 2020-03-16 | 2026-08-07 |
| Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) Osimertinib, Savolitinib, Gefitinib - Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | AstraZeneca | 247 | 2019-06-25 | 2025-01-30 |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors Selpercatinib - Medullary Thyroid Cancer, Infantile Myofibromatosis | Phase 1 / Phase 2 | Active not recruiting | Eli Lilly and Company | 36 | 2019-06-13 | 2026-01-06 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-07-24 |
| A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) LOXO-292 - Non-Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Active not recruiting | Eli Lilly and Company | 857 | 2017-05-02 | 2026-04-16 |
| The Drug Rediscovery Protocol (DRUP Trial) Panitumumab, Olaparib, Dabrafenib - Cancer, Tumors | Phase 2 | Recruiting | The Netherlands Cancer Institute | 1550 | 2016-08-01 | 2024-01-24 |
Carcinoma, Non-Small-Cell Lung (7) · Thyroid Neoplasms (5) · Carcinoma, Medullary (4) · Lung Neoplasms (4) · Thyroid Cancer, Papillary (4) · Breast Neoplasms (3) · Central Nervous System Neoplasms (3) · Neoplasms (3) · Sarcoma (3) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Colonic Neoplasms (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Ependymoma (2)
Eli Lilly and Company (3) · National Cancer Institute (NCI) (2) · SWOG Cancer Research Network (2) · AstraZeneca (1) · Fondazione per la Medicina Personalizzata (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · The Netherlands Cancer Institute (1)
United States (9) · Australia (4) · Italy (4) · Canada (3) · Denmark (3) · Japan (3) · South Korea (3) · Spain (3) · France (2) · Germany (2) · Netherlands (2) · Puerto Rico (2) · United Kingdom (2) · China (1) · Hong Kong (1)
Yasir Y Elamin (2) · Andrea Botticelli (1) · Andrea T Franson (1) · Donald W Parsons (1) · E.E. Voest, prof. (1) · Helena A Yu, MD (1) · Lori J. Wirth, MD (1) · Mark Zafereo (1) · Paolo Marchetti (1)
PMID 32027845, PMID 32846060, PMID 32846061, PMID 33591402, PMID 34088726, PMID 34389237, PMID 35086719, PMID 35353553, PMID 35598186, PMID 35923928, PMID 35930972, PMID 36062046, PMID 36108661, PMID 36122315, PMID 36657661, PMID 36870947, PMID 37265412, PMID 37315261, PMID 37424386, PMID 37655205, PMID 37934000, PMID 38630551, PMID 38661071, PMID 39085487, PMID 39094065, PMID 39471424, PMID 39521433, PMID 39759832, PMID 39983053, PMID 40466026, PMID 41023484, PMID 41130408, PMID 41166674, PMID 41780641, PMID 41963505, PMID 41986720, PMID 42361644, PMID 42686334, PMID 42867148, PMID 42874021
2018 (2), 2023 (2), U10CA180886 (2), U10CA180888 (2), 2017 (1), 2019 (1)